Related Experiment Video
Updated: Jul 4, 2026

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
Published on: August 31, 2014
Mpox Vaccine Hesitancy Among Sexually Active People with HIV in Care at Risk for mpox
R J Fredericksen1, L S Mixson2, R M Nance2
1Department of Medicine, University of Washington, Seattle, WA, USA. rfrederi@uw.edu.
Abstract:
Mpox has particularly adverse effects among people with HIV (PWH). We examined mpox vaccine utilization and hesitancy among men who have sex with men (MSM), and transgender women (TW) in HIV care in a multisite U.S. cohort. We queried MSM/TW reporting past 3-month sexual activity at 7 Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) sites regarding mpox vaccination status, and willingness and hesitancy to vaccinate via questionnaires self-administered at routine HIV care visits between 1/2023 and 4/2024. We measured bivariate cross-sectional associations between vaccination status and demographic characteristics; among those reporting no vaccination, we measured associations between hesitancy and demographic characteristics. Among MSM/TW (n = 1146, mean age 46; 97% cisgender MSM, 3% TW; 46% white, 39% Black, 11% Hispanic), 52% (n = 597) reported not being vaccinated against mpox. Of these, 33% (n = 195) indicated they were not likely to be vaccinated despite provider recommendation. A higher proportion of Black respondents indicated they would not get vaccinated compared with white or Hispanic (42% vs. 23% and 33%, respectively; p ≤ 0.001). Key reasons were health concerns (57%, highest among Black participants, p ≤ 0.001), particularly concerns that 'not enough is known' about the vaccine (47%), side effects (25%), and low perceived acquisition risk (33%). Among sexually active MSM/TW in HIV care, mpox vaccine hesitancy was highest among persons of Black race. Common reasons were concerns about negative health effects, the belief that not enough is known about the vaccine, and low perceived risk. Education efforts should highlight mpox vaccine safety as well as mpox transmission risk.
Insights
Mpox vaccine hesitancy is high among men who have sex with men and transgender women in HIV care, especially Black individuals. Concerns include vaccine safety and perceived low risk of mpox infection.
Area of Science:
- Public Health
- Infectious Disease Epidemiology
- Vaccinology
Background:
- Mpox (formerly monkeypox) poses significant health risks, particularly to people with HIV (PWH).
- Understanding mpox vaccine uptake and hesitancy is crucial for targeted public health interventions.
- Men who have sex with men (MSM) and transgender women (TW) are disproportionately affected by mpox.
Purpose of the Study:
- To examine mpox vaccine utilization and hesitancy among MSM and TW receiving HIV care.
- To identify demographic factors associated with mpox vaccine hesitancy in this population.
- To understand the primary reasons for mpox vaccine hesitancy.
Main Methods:
- A cross-sectional study was conducted among sexually active MSM and TW in HIV care across 7 U.S. Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) sites.
- Data were collected via self-administered questionnaires on mpox vaccination status, willingness, and hesitancy between January 2023 and April 2024.
- Bivariate analyses assessed associations between vaccination status, hesitancy, and demographic characteristics.
Main Results:
- Over half (52%) of the 1146 participants reported not being vaccinated against mpox.
- Among unvaccinated individuals, 33% expressed unwillingness to vaccinate, with higher rates among Black respondents (42%) compared to white (23%) or Hispanic (33%) individuals.
- Key reasons for hesitancy included health concerns (57%), insufficient knowledge about the vaccine (47%), side effects (25%), and low perceived risk of mpox acquisition (33%).
Conclusions:
- Mpox vaccine hesitancy is substantial among sexually active MSM and TW in HIV care, particularly within the Black community.
- Addressing concerns about vaccine safety, knowledge gaps, and perceived risk is essential for improving mpox vaccination coverage.
- Public health education should emphasize both the safety of mpox vaccines and the risks associated with mpox transmission.
Related Concept Videos
Vaccinations
Sexually Transmitted Infections
Vaccines
Smallpox
Genital Herpes
Amebiasis

